Alcon Research
Alcon Research sponsors 275 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 248 completed. 87 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cataract, with 12 trials.
Trial Pipeline
275 total, page 6 of 6
Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery
NCT00333255
Anecortave Acetate Risk-Reduction Trial (AART)
NCT00333216
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
NCT00299507
Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles
NCT00383201
Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus
NCT00333268
Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients
NCT00382603
Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses
NCT00382902
Evaluation of an Investigational Multi-Purpose Disinfecting Solution for Care of Soft Contact Lenses
NCT00382681
Anecortave Acetate Risk-Reduction Trial (AART)
NCT00307398
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
NCT00065728
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
NCT00061503
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
NCT00058994
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00061529
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
NCT00061542
A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension
NCT00051194
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
NCT00041483
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
NCT00047541
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
NCT00051142
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
NCT00051155
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69
NCT00047515
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
NCT00047528
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
NCT00346866
Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98
NCT00047593
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
NCT00051181
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
NCT00069719
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 23 |
| Phase 3 | 47 |
| Phase 4 | 40 |
Therapeutic Areas
What the Pipeline for Alcon Research Shows
According to the ClinicalTrials.gov registry, Alcon Research is linked to 275 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting, about 2% of the sponsor's indexed portfolio, and 248 are already marked complete, representing roughly 90% of the total.
The phase mix for Alcon Research reports 87 late-stage studies (Phase 3 and Phase 4 combined) and 28 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Alcon Research is Cataract with 12 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.